Tony Coles, former Onyx Pharmaceuticals CEO, joins CNBC's Bertha Coombs at the Forbes Healthcare conference to discuss the government shutdown's impact on health care and Obamacare.» Read More
Tony Coles, CEO of Onyx Pharmaceuticals, appeared on Monday's "Fast Money Halftime Report." Also, check out what was said after the broadcast in web exclusive video.
Onyx Pharmaceuticals CEO Tony Coles reveals the next two areas to watch in the Biotech sector.
Get an exclusive update on cancer drug trials and the biotech industry from Onyx Pharmaceutical CEO Dr. Tony Coles.
Stocks pulled off a gain Tuesday after a see-saw session as techs and industrials gained, while energy and bank stocks were weak.
I've never been to San Antonio. I've heard great things about it, especially the downtown and the river that runs through it, but haven't been able to check it out yet.
A key hematology conference and earnings reports offer investors six stocks to watch.
No doubt the widespread use of solar and wind power is ideal, but it’ll be a long time before the mass adoption of those alternative energies is a reality. In the meantime, Cramer says, the US should shift its focus to natural gas.
These firms would make great acquisitions for big drug companies looking to expand their cancer portfolios.
The Lightning Round is extended in this CNBC.com exclusive feature.
Stocks shot out of the gate Monday, fueled by earnings optimism, but then pulled back near the final hour of trading as investors took some profits.
Stocks opened higher Monday as better-than-expected third-quarter results began trickling in, boosting investors' optimism about the overall earnings season.
Futures indicated a mildly higher open for Wall Street on Monday as better-than-expected third-quarter results began trickling in, boosting investors' optimism about the overall earnings season.
Plus, Cramer makes the call on Obama's health-care plans, smartphone data overload and more.
When it rains, it pours. I mean, what a crazy Monday for deals and data in biopharma.
Following are the day’s biggest winners and losers. Find out why shares of Garmin and Ralph Lauren popped while Electronic Arts and Onyx Pharma dropped.
Everyone’s talking about the July stock market rally. And, of course, you can’t overlook the outperformance of biotech—big and small.
What a week! And there's still one day left. Human Genome Sciences and Orexigen got the party started on Monday with their Lupus and diet drug data, respectively. Onyx Pharmaceuticals was a surprise guest with its mid-stage breast cancer results on Wednesday. Bristol-Myers Squibb cranked up the volume late yesterday with its two-bagger for Medarex. And then this morning Celgene announced it had stopped a multiple myeloma study early because the drug appears to be working so well.
Consumers may be saving more and spending less, but big pharma is on a shopping spree. And I'm not talking about the really big deals including Roche buying Genentech, Pfizer buying Wyeth and Merck buying Schering-Plough. I'm talking about the two deals that have been done in less than a week between major drug companies and baby biotechs specializing in oncology.
Will M&A activity boost biotech stocks in 2009?
Cramer makes the call on viewers' favorite stocks.